Skip to content
Bonusworks UK

The Zimbabwean Government Turns Down ‘Lopsided’ American Health Aid Agreement Due to Data Fears

Health funding image
The proposed US financial assistance was intended for initiatives for HIV/Aids treatment and prevention, tuberculosis, and malaria.

The nation of Zimbabwe has declined a major American health deal worth $367m (£272m) spanning five years due to Washington's insistence on sensitive biological samples.

The decision became public following a government memo from December was disclosed, indicating that President Emmerson Mnangagwa deemed the deal was "unbalanced".

An official spokesman later clarified that the United States was requesting biological samples for scientific study and commercial purposes while was unwilling to guarantee the resulting advantages from future treatments.

"We must now begin the challenging and unfortunate process of ending our support in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.

Her embassy indicated the United States had provided more than $1.9bn as health assistance to Zimbabwe during the past two decades.

A doctors' association in Zimbabwe has appealed for more dialogue to secure a agreement suitable to both sides so the country's vital HIV programme can continue.

Wider Context

This rejection follows a comparable case in Kenya, where a court suspended a similar deal with the US following legal challenges were raised about the security of citizens' health data.

Since resuming the presidency recently, US President Donald Trump has drastically cut overseas assistance and shut down the key foreign aid agency.

USAID had managed aid for the American government, but Trump claimed its expenditure was "wasteful" and his administration was seeking government-to-government agreements to enhance transparency and accountability.

As per statements, 16 nations in Africa have so far agreed to these new health pacts, constituting more than $18.3bn in new funding.

Details of the Declined Deal

The money for Zimbabwe would have supported "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.

"We are confident this collaboration would have delivered extraordinary benefits for the people of Zimbabwe, especially the 1.2 million men, women and children currently receiving antiretroviral therapy via US-supported programmes," the Ambassador commented.

However, government spokesperson Nick Mangwana maintained the proposed deal was "asymmetrical".

"The proposal required Zimbabwe to surrender its genetic material and health information for a long time, with no corresponding promise of benefiting from any scientific breakthroughs – such as new medicines or tests – that might be developed from that shared data," his statement read.

"In essence, our nation would provide the basic resources for scientific discovery with no assurance that the end products would be available to our citizens if a future disease outbreak emerge."

Sovereignty and Global Health

Mangwana further pointed out that the US's withdrawal from the global health body and its push of bilateral health agreements were undermining frameworks previously set up through the global health agency.

The spokesperson gave as an example its Pandemic Benefit-Sharing framework created to deal with future pandemics.

"This system is intended to guarantee that when a nation contributes its samples, the benefits – including medicines and cures – are distributed fairly, not monopolised exclusively by those with the funds to create them."

Zimbabwe's reservations regarding the US deal "should not be misconstrued as hostility towards the US," Mangwana stressed.

"We are open to continued dialogue with our US partners on how future collaboration might be designed in a way that honours the independence and interests of each country."

Medical Community Response

A leading public health body stated it understood the government's concerns, but suggested that negotiations need to persist since much of the nation's HIV programmes were funded by external financing.

"In cases where technical issues exist, including those involving data governance or implementation frameworks, these can frequently be addressed through technical clarification and mutually agreed protections," it said.

The situation underscores the ongoing debate between receiving much-needed foreign assistance and safeguarding a country's data in an ever more data-driven world.

TR
Written by

Timothy Roman

Elena Harper is a finance enthusiast and deal hunter with over a decade of experience in helping UK consumers maximize their savings through bonuses and rewards.

Bonusworks UK

Type to search articles.